Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies

Annals of Internal Medicine

Volumn 158, Issue 5 PART 1, 2013, Pages 329-337

  Morgan, Rebecca L ^a   Baack, Brittney ^a   Smith, Bryce D ^a   Yartel, Anthony ^a   Pitasi, Marc ^b   Falck Ytter, Yngve ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; ERADICATION THERAPY; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SUSTAINED VIROLOGIC RESPONSE; SYSTEMATIC REVIEW;

EID: 84874725554     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-5-201303050-00005     Document Type: Review

References (67)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Globocan 2008: Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. Accessed at http://globocan.iarc.fr on 6 November 2012.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14. [PMID: 16702586]
3. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-82. [PMID: 10706572]
4. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance-United States, 2010. Atlanta: Centers for Disease Control and Prevention; 2012: 1-71.
5. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-70. [PMID: 22056542]
6. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55:1344-55. [PMID: 22135116]
7. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-8. [PMID: 22351712]
8. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-91. [PMID: 19224838]
9. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37 Suppl 2:S88-94. [PMID: 17877502]
10. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005; 9:383-98. [PMID: 16023972]
11. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43: 66-72. [PMID: 20739252]
12. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74. [PMID: 19330875]
13. Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, et al. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin. J Gastroenterol Hepatol. 2012;27:69-75. [PMID: 21649727]
14. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-516 [PMID: 21397729]
15. Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34:748-55. [PMID: 11434622]
16. Calvaruso V, Di Marco V, Ferraro D, Pizzillo P, Alaimo G, Craxì A. Liver related events and survival in patients with compensated HCV cirrhosis: the role of sustained virological response to PEG-IFN based therapy and portal hypertension. Presented at Italian Association for the Study of the Liver Annual Meeting 2011, 24 -25 February 2011, Rome, Italy. Dig Liver Dis. 2011;43:S99. Downloaded From: http://annals.org/byaElsevierBVUseron03/05/2013
17. Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, et al; HENCORE Group. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat. 2007;14:556-63. [PMID: 17650289]
18. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8: 280-8, 288. [PMID: 19948249]
19. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-44. [PMID: 21898493]
20. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16. [PMID: 21696307]
21. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206. [PMID: 21449783]
22. Cammà C, Di Bona D, Craxì A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Des. 2004;10:2123-30. [PMID: 15279551]
23. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010;8:192-9. [PMID: 19879972]
24. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer. 2011;129:1254-64. [PMID: 21710498]
25. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:923-30. [PMID: 21699815]
26. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889-900. [PMID: 21427396]
27. Kramer JR, Davila JA, Duan Z, Richardson PA, Kanwal F, El-Serag H. Antiviral treatment for hepatitis C virus is associated with a reduced risk of hepatocellular carcinoma in a national cohort of U.S. veterans. Presented at Digestive Disease Week 2011, 7-11 May 2011, Chicago. Gastroenterology. 2011; 140(5 Suppl 1):S899.
28. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ontario, Canada: Ottawa Hospital Research Institute; 2011. Accessed at www.ohri.ca/programs/clinical_epidemiology/oxford.htm on 14 November 2012.
29. Schünemann H, Brozek J, Guyatt G, Oxman A, eds. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.6. Hamilton, Ontario, Canada: McMaster University, GRADE Working Group; 2011. Accessed at http://ims.cochrane.org/revman/gradepro on 14 November 2012.
30. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. [PMID: 18436948]
31. Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10:54. [PMID: 20537177]
32. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193-206. [PMID: 16784338]
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
34. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993; 2:121-45. [PMID: 8261254]
35. Greenland S, Rothman KJ. Introduction to categorical statistics. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998;231-52.
36. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52:518-27. [PMID: 20683951]
37. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol. 2007;13:5648-53. [PMID: 17948941]
38. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al; Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-87. [PMID: 17326216]
39. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009;104:1147-58. [PMID: 19352340]
40. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652-7. [PMID: 20346533]
41. Cheinquer N, Cheinquer H, Wolff FH, Coelho-Borges S. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. Braz J Infect Dis. 2010;14:457-61. [PMID: 21221473]
42. D'Ambrosio R, Aghemo A, Rumi MG, Primignani M, Dell'Era A, Lampertico P, et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther. 2011;16:677-84. [PMID: 21817189]
43. Dohmen K, Takahashi K, Kawano A, Shigematsu H, Tanaka H, Ichiki Y, et al. Development of hepatocellular carcinoma after peginterferon plus ribavirin therapy in chronic hepatitis C. Presented at 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011, 4 8 November 2011, San Francisco. Hepatology. 2011;54:1400A.
44. Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, SanchezTapias JM, Rincón D, et al; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR). Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105:2164-72. [PMID: 20700116]
45. Giannini E, Fasoli A, Botta F, Testa E, Romagnoli P, Ceppa P, et al. Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: a functional study. J Gastroenterol Hepatol. 2001;16:399-405. [PMID: 11354278]
46. Hung CH, Lee CM, Wang JH, Hu TH, Chen CH, Lin CY, et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer. 2011; 128:2344-52. [PMID: 20669224]
47. Iacobellis A, Perri F, Valvano MR, Caruso N, Niro GA, Andriulli A. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol. 2011;9:249-53. [PMID: 21092761]
48. Jamil KM, Cheng W, Tarquinio L, Adams L, Mollison L, Macquillan G, et al. The risk of hepatocellular carcinoma and decompensation following hepatitis C treatment with interferon-based therapy. Gut. 2007;56:A126.
49. Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, et al. A prospective comparison of the effect of interferon-alpha and interferonbeta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother. 2003;9:333-40. [PMID: 14691655]
50. Kawamura Y, Arase Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, et al. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med. 2010;123:951-956 [PMID: 20920698]
51. Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, et al. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res. 2009; 39:432-8. [PMID: 19207583]
52. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833-44. [PMID: 20564351]
53. Okanoue T, Itoh Y, Kirishima T, Daimon Y, Toyama T, Morita A, et al. Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res. 2002;23:62-77. [PMID: 12084557]
54. Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, et al. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol. 2012;47:444-51. [PMID: 22105231]
55. Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology. 2001;33: 1299-302. [PMID: 11343259]
56. Sinn DH, Paik SW, Kang P, Kil JS, Park SU, Lee SY, et al. Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int. 2008; 28:1363-9. [PMID: 18710426]
57. Takahashi H, Mizuta T, Eguchi Y, Kawaguchi Y, Kuwashiro T, Oeda S, et al. Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol. 2011;46:790-8. [PMID: 21331763]
58. Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92-100. [PMID: 20711614]
59. Tamura Y, Yamagiwa S, Aoki Y, Kurita S, Suda T, Ohkoshi S, et al; Niigata Liver Disease Study Group. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci. 2009;54:2530-7. [PMID: 19093203]
60. Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-61. [PMID: 21374066]
61. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131:174-81. [PMID: 10428733]
62. Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol. 2004;99:636-44. [PMID: 15089895]
63. van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Factors associated with hepatocellular carcinoma in chronic hepatitis C patients with advanced liver fibrosis. J Hepatol. 2012;56(S2): S363-4.
64. Hasegawa E, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, et al. Efficacy and anticarcinogenic activity of interferon for hepatitis C virusrelated compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. Hepatol Res. 2007;37:793-800. [PMID: 17593231]
65. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, et al. Longterm effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13:409-14. [PMID: 16842444]
66. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al; Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105-14. [PMID: 15657158]
67. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al; HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006;44:1675-84. [PMID: 17133499]